Feed CYBN
CY

Cybin Inc.

CYBN · AMEX

$8.28 +1.22% (+$0.10)
Piotroski F-Score Weak
0/9
Valuation
-
N/A
P/E N/A
PEG N/A
EV/EBITDA N/A
Growth
-
N/A
EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
-
N/A
ROIC N/A
Asset turnover N/A
ROE N/A
Debt
-
N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio N/A
Stability
100 /100
Stable
Beta 0.79x
Rev. volatility N/A
Profitable years N/A

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CYBN
Online

About the company

Cybin Inc. (CYBN) is a biotechnology company specializing in the development of therapeutic therapies based on psychedelic compounds for the treatment of various mental disorders. The company focuses on developing medications that utilize psychedelic substances such as psilocybin to support the treatment of conditions like depression, anxiety disorders, and post-traumatic stress disorder. Cybin Inc. is engaged in clinical studies and research to provide new treatment options for patients suffering from mental illnesses. With the growing interest in alternative therapeutic approaches in the field of mental health, Cybin Inc. has the potential for sustained growth. Cybin Inc. (CYBN) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies based on psychedelic compounds industry.

Sector

Healthcare

Industry

Biotechnology

CEO

Eric So

Employees

50

Headquarters

Toronto

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.